Format

Send to

Choose Destination
Am J Clin Pathol. 2014 Jul;142(1):7-15. doi: 10.1309/AJCPU6OOKL9JHEUR.

Pathology consultation on prostate-specific antigen testing.

Author information

1
From the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA. jaime.noguez@emory.edu.
2
From the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.

Abstract

OBJECTIVES:

To provide clarity on the pros and cons of using prostate-specific antigen (PSA) as a screening tool for prostate cancer.

METHODS:

Case scenarios and a literature review of recently published clinical trial data are presented to provide evidence of the controversy.

RESULTS:

PSA is a sensitive biomarker for detecting diseases of the prostate, but it is limited in its ability to distinguish cancerous from noncancerous conditions or aggressive from indolent cancers and has resulted in a considerable amount of overdiagnosis and overtreatment.

CONCLUSIONS:

The analytical methodology for total PSA testing is both reliable and cost-effective, but patients should be encouraged to talk to their providers to understand the benefits and harms associated with this testing.

KEYWORDS:

Prostate cancer; Prostate-specific antigen; Screening

PMID:
24926079
DOI:
10.1309/AJCPU6OOKL9JHEUR
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center